From where we were at the beginning, it is massive improvements, and the more people that join the study, the better it’s going to get.” ...

SNIPR Biome has said its CRISPR therapeutic targeting a problem bacterial pathogen has shown proof-of-concept in a phase 1 trial ... Escherichia coli in the human gastrointestinal tract, including ...